Journal Article

A randomized clinical trial assessing theranostic-guided corneal cross-linking for treating keratoconus: the ARGO protocol

Roszkowska, Anna Maria, Alunni Fegatelli, Danilo, Lombardo, Giuseppe, Giannaccare, Giuseppe, Bernava, Giuseppe Massimo, Scorcia, Vincenzo, Lombardo, Marco, Vestri, Annarita, Serrao, Sebastiano, Mencucci, Rita

2023

Overview

The Assessment of theranostic guided riboflavin/UV-A corneal cross-linking for treatment of keratoconus (ARGO; registration number NCT05457647) clinical trial tests the hypothesis that theranostic-guided riboflavin/UV-A corneal cross-linking (CXL) can provide predictable clinical efficacy for halting keratoconus progression, regardless of treatment protocol, i.e., either with or without epithelial removal. Theranostics is an emerging therapeutic paradigm of personalized and precision medicine that enables real-time monitoring of image-guided therapy. In this trial, the theranostic software module of a novel UV-A medical device will be validated in order to confirm its accuracy in estimating corneal cross-linking efficacy in real time. During CXL procedure, the theranostic UV-A medical device will provide the operator with an imaging biomarker, i.e., the theranostic score, which is calculated by non-invasive measurement of corneal riboflavin concentration and its UV-A light mediated photo-degradation. ARGO is a randomized multicenter clinical trial in patients aged between 18 and 40 years with progressive keratoconus aiming to validate the theranostic score by assessing the change of the maximum keratometry point value at 1-year postoperatively. A total of 50 participants will be stratified with allocation ratio 1:1 using a computer-generated stratification plan with blocks in two treatment protocols, such as epithelium-off or epithelium-on CXL. Following treatment, participants will be monitored for 12 months. Assessment of safety and performance of theranostic-guided corneal cross-linking treatment modality will be determined objectively by corneal tomography, corneal endothelial microscopy, visual acuity testing and slit-lamp eye examination.

• Publisher: Springer Netherlands,Springer Nature B.V
• Subject: Acuity / Adolescent / Adult / Biomarkers / Clinical trials / Cornea / Cornea - metabolism / Corneal Cross-Linking / Corneal Topography / Cross-Linking Reagents - therapeutic use / Crosslinking / Effectiveness / Epithelium / Health services / Humans / Keratoconus / Keratoconus - diagnosis / Keratoconus - drug therapy / Keratoconus - surgery / Medical devices / Medical equipment / Medicine / Medicine & Public Health / Multicenter Studies as Topic / New Treatments for Keratoconus / Ophthalmology / Original Paper / Photochemotherapy - methods / Photodegradation / Photosensitizing Agents - therapeutic use / Precision Medicine / Randomized Controlled Trials as Topic / Real time / Riboflavin / Riboflavin - therapeutic use / Ultraviolet Rays / Visual acuity / Vitamin B / Young Adult